vs
Apellis Pharmaceuticals, Inc.（APLS）与FIGS, Inc.（FIGS）财务数据对比。点击上方公司名可切换其他公司
FIGS, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.0倍（$201.9M vs $199.9M），FIGS, Inc.净利率更高（9.2% vs -29.5%，领先38.7%），FIGS, Inc.同比增速更快（33.0% vs -5.9%），FIGS, Inc.自由现金流更多（$58.1M vs $-14.3M），过去两年FIGS, Inc.的营收复合增速更高（30.1% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
FIGS是一家总部位于美国加利福尼亚州圣莫尼卡的服饰企业，由希瑟·哈森与特里娜·斯皮尔于2013年共同创立，二人目前共同担任首席执行官。品牌专注为医疗从业者提供医用刷手服及相关专业产品，是医疗工装领域的知名品牌。
APLS vs FIGS — 直观对比
营收规模更大
FIGS
是对方的1.0倍
$199.9M
营收增速更快
FIGS
高出38.9%
-5.9%
净利率更高
FIGS
高出38.7%
-29.5%
自由现金流更多
FIGS
多$72.3M
$-14.3M
两年增速更快
FIGS
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $201.9M |
| 净利润 | $-59.0M | $18.5M |
| 毛利率 | — | 62.9% |
| 营业利润率 | -25.6% | 9.3% |
| 净利率 | -29.5% | 9.2% |
| 营收同比 | -5.9% | 33.0% |
| 净利润同比 | -62.2% | 881.8% |
| 每股收益（稀释后） | $-0.40 | $0.10 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSFIGS
| Q4 25 | $199.9M | $201.9M | ||
| Q3 25 | $458.6M | $151.7M | ||
| Q2 25 | $178.5M | $152.6M | ||
| Q1 25 | $166.8M | $124.9M | ||
| Q4 24 | $212.5M | $151.8M | ||
| Q3 24 | $196.8M | $140.2M | ||
| Q2 24 | $199.7M | $144.2M | ||
| Q1 24 | $172.3M | $119.3M |
净利润APLSFIGS
| Q4 25 | $-59.0M | $18.5M | ||
| Q3 25 | $215.7M | $8.7M | ||
| Q2 25 | $-42.2M | $7.1M | ||
| Q1 25 | $-92.2M | $-102.0K | ||
| Q4 24 | $-36.4M | $1.9M | ||
| Q3 24 | $-57.4M | $-1.7M | ||
| Q2 24 | $-37.7M | $1.1M | ||
| Q1 24 | $-66.4M | $1.4M |
毛利率APLSFIGS
| Q4 25 | — | 62.9% | ||
| Q3 25 | — | 69.9% | ||
| Q2 25 | — | 67.0% | ||
| Q1 25 | — | 67.6% | ||
| Q4 24 | — | 67.3% | ||
| Q3 24 | — | 67.1% | ||
| Q2 24 | — | 67.4% | ||
| Q1 24 | — | 68.9% |
营业利润率APLSFIGS
| Q4 25 | -25.6% | 9.3% | ||
| Q3 25 | 48.7% | 6.4% | ||
| Q2 25 | -18.6% | 6.5% | ||
| Q1 25 | -50.0% | -0.2% | ||
| Q4 24 | -12.3% | 5.9% | ||
| Q3 24 | -24.0% | -6.2% | ||
| Q2 24 | -14.7% | 1.1% | ||
| Q1 24 | -36.0% | 0.4% |
净利率APLSFIGS
| Q4 25 | -29.5% | 9.2% | ||
| Q3 25 | 47.0% | 5.8% | ||
| Q2 25 | -23.6% | 4.7% | ||
| Q1 25 | -55.3% | -0.1% | ||
| Q4 24 | -17.1% | 1.2% | ||
| Q3 24 | -29.2% | -1.2% | ||
| Q2 24 | -18.9% | 0.8% | ||
| Q1 24 | -38.5% | 1.2% |
每股收益（稀释后）APLSFIGS
| Q4 25 | $-0.40 | $0.10 | ||
| Q3 25 | $1.67 | $0.05 | ||
| Q2 25 | $-0.33 | $0.04 | ||
| Q1 25 | $-0.74 | $0.00 | ||
| Q4 24 | $-0.30 | $0.01 | ||
| Q3 24 | $-0.46 | $-0.01 | ||
| Q2 24 | $-0.30 | $0.01 | ||
| Q1 24 | $-0.54 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $437.5M |
| 总资产 | $1.1B | $580.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSFIGS
| Q4 25 | $466.2M | $82.0M | ||
| Q3 25 | $479.2M | $46.5M | ||
| Q2 25 | $370.0M | $50.8M | ||
| Q1 25 | $358.4M | $90.0M | ||
| Q4 24 | $411.3M | $85.6M | ||
| Q3 24 | $396.9M | $124.1M | ||
| Q2 24 | $360.1M | $131.8M | ||
| Q1 24 | $325.9M | $155.3M |
总债务APLSFIGS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSFIGS
| Q4 25 | $370.1M | $437.5M | ||
| Q3 25 | $401.2M | $413.3M | ||
| Q2 25 | $156.3M | $396.5M | ||
| Q1 25 | $164.2M | $381.5M | ||
| Q4 24 | $228.5M | $377.1M | ||
| Q3 24 | $237.1M | $403.5M | ||
| Q2 24 | $264.3M | $401.7M | ||
| Q1 24 | $266.7M | $389.9M |
总资产APLSFIGS
| Q4 25 | $1.1B | $580.0M | ||
| Q3 25 | $1.1B | $544.7M | ||
| Q2 25 | $821.4M | $517.1M | ||
| Q1 25 | $807.3M | $522.3M | ||
| Q4 24 | $885.1M | $509.8M | ||
| Q3 24 | $901.9M | $542.5M | ||
| Q2 24 | $904.5M | $526.0M | ||
| Q1 24 | $831.9M | $510.9M |
负债/权益比APLSFIGS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $60.9M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $58.1M |
| 自由现金流率自由现金流/营收 | -7.1% | 28.8% |
| 资本支出强度资本支出/营收 | 0.1% | 1.4% |
| 现金转化率经营现金流/净利润 | — | 3.29× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $53.0M |
8季度趋势，按日历期对齐
经营现金流APLSFIGS
| Q4 25 | $-14.2M | $60.9M | ||
| Q3 25 | $108.5M | $3.4M | ||
| Q2 25 | $4.4M | $-12.4M | ||
| Q1 25 | $-53.4M | $9.2M | ||
| Q4 24 | $19.4M | $30.4M | ||
| Q3 24 | $34.1M | $22.6M | ||
| Q2 24 | $-8.3M | $16.5M | ||
| Q1 24 | $-133.0M | $11.6M |
自由现金流APLSFIGS
| Q4 25 | $-14.3M | $58.1M | ||
| Q3 25 | $108.3M | $531.0K | ||
| Q2 25 | $4.4M | $-13.5M | ||
| Q1 25 | $-53.4M | $7.9M | ||
| Q4 24 | $19.3M | $27.1M | ||
| Q3 24 | — | $18.4M | ||
| Q2 24 | $-8.4M | $7.5M | ||
| Q1 24 | $-133.3M | $11.1M |
自由现金流率APLSFIGS
| Q4 25 | -7.1% | 28.8% | ||
| Q3 25 | 23.6% | 0.4% | ||
| Q2 25 | 2.5% | -8.9% | ||
| Q1 25 | -32.0% | 6.3% | ||
| Q4 24 | 9.1% | 17.8% | ||
| Q3 24 | — | 13.1% | ||
| Q2 24 | -4.2% | 5.2% | ||
| Q1 24 | -77.3% | 9.3% |
资本支出强度APLSFIGS
| Q4 25 | 0.1% | 1.4% | ||
| Q3 25 | 0.0% | 1.9% | ||
| Q2 25 | 0.0% | 0.7% | ||
| Q1 25 | 0.0% | 1.0% | ||
| Q4 24 | 0.0% | 2.2% | ||
| Q3 24 | 0.0% | 3.0% | ||
| Q2 24 | 0.0% | 6.2% | ||
| Q1 24 | 0.2% | 0.4% |
现金转化率APLSFIGS
| Q4 25 | — | 3.29× | ||
| Q3 25 | 0.50× | 0.39× | ||
| Q2 25 | — | -1.75× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 16.14× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 15.04× | ||
| Q1 24 | — | 8.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
FIGS
| Scrubwear | $154.9M | 77% |
| Non Scrubwear Lifestyle | $47.0M | 23% |
